Loading...
Market
Side Effects Observed in Initial HRO761 Clinical Trials
5
Resolution / Starting Odds
No significant side effects • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Clinical trial results published in a peer-reviewed medical journal or press releases from NIBR or Vividion
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
No significant side effects • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Does not progress past Phase 1 • 25%
Completes Phase 1 but not Phase 2 • 25%
Completes Phase 2 but not Phase 3 • 25%
Advances to Phase 3 or beyond • 25%
Improved patient outcomes • 33%
Mixed or unchanged outcomes • 33%
Negative outcomes or side effects • 34%
Successful with no major side effects • 33%
Successful with manageable side effects • 33%
Unsuccessful due to efficacy or safety issues • 34%
Significant improvement • 33%
Moderate improvement • 34%
No improvement or worsening • 33%
Highly positive outcomes • 25%
Moderately positive outcomes • 25%
Neutral outcomes • 25%
Negative outcomes • 25%